Prominent publications by Charles W Olanow

KOL Index score: 17367

BACKGROUND: The ADAGIO study investigated whether rasagiline has disease-modifying effects in Parkinson's disease. Rasagiline 1 mg per day, but not 2 mg per day, was shown to be efficacious in the primary analysis. Here, we report additional secondary and post-hoc analyses of the ADAGIO study.

METHODS: ADAGIO was a placebo-controlled, double-blind, multicentre, delayed-start study, in which 1176 patients with untreated early Parkinson's disease were randomly assigned to receive ...

Also Ranks for: Adagio Study |  updrs scores |  36 weeks |  rasagiline placebo |  week difference
KOL Index score: 16813

BACKGROUND: A therapy that slows disease progression is the major unmet need in Parkinson's disease.

METHODS: In this double-blind trial, we examined the possibility that rasagiline has disease-modifying effects in Parkinson's disease. A total of 1176 subjects with untreated Parkinson's disease were randomly assigned to receive rasagiline (at a dose of either 1 mg or 2 mg per day) for 72 weeks (the early-start group) or placebo for 36 weeks followed by rasagiline (at a dose of either 1 ...

Also Ranks for: 1 Day |  updrs score |  week earlystart |  early treatment |  rasagiline parkinsons disease
KOL Index score: 16289

Mutations in Leucine-rich repeat kinase 2 (LRRK2) are linked to the most common familial forms and some sporadic forms of Parkinson's disease (PD). The LRRK2 protein contains two well-known functional domains, MAPKKK-like kinase and Rab-like GTPase domains. Emerging evidence shows that LRRK2 contains kinase activity which is enhanced in several PD-associated mutants of LRRK2. However, the GTPase activity of LRRK2 has yet to be formally demonstrated. Here, we produced and purified the ...

Also Ranks for: Gtpase Activity |  repeat kinase |  familial parkinson |  lrrk2 protein |  serine threonine
KOL Index score: 15239

BACKGROUND: Increased neuronal activity in the subthalamic nucleus and the pars interna of the globus pallidus is thought to account for motor dysfunction in patients with Parkinson's disease. Although creating lesions in these structures improves motor function in monkeys with induced parkinsonism and patients with Parkinson's disease, such lesions are associated with neurologic deficits, particularly when they are created bilaterally. Deep-brain stimulation simulates the effects of a ...

Also Ranks for: Globus Pallidus |  subthalamic nucleus |  pars interna |  patients parkinsons disease |  motor function
KOL Index score: 13660

BACKGROUND: Despite the known benefit of levodopa in reducing the symptoms of Parkinson's disease, concern has been expressed that its use might hasten neurodegeneration. This study assessed the effect of levodopa on the rate of progression of Parkinson's disease.

METHODS: In this randomized, double-blind, placebo-controlled trial, we evaluated 361 patients with early Parkinson's disease who were assigned to receive carbidopa-levodopa at a daily dose of 37.5 and 150 mg, 75 and 300 mg, or ...

Also Ranks for: Levodopa Placebo |  progression parkinsons disease |  updrs baseline |  daily dose |  40 weeks
KOL Index score: 13609

This article presents the revision process, major innovations, and clinimetric testing program for the Movement Disorder Society (MDS)-sponsored revision of the Unified Parkinson's Disease Rating Scale (UPDRS), known as the MDS-UPDRS. The UPDRS is the most widely used scale for the clinical study of Parkinson's disease (PD). The MDS previously organized a critique of the UPDRS, which cited many strengths, but recommended revision of the scale to accommodate new advances and to resolve ...

Also Ranks for: Clinimetric Testing |  movement disorder society |  rating scale |  unified parkinson |  mdsupdrs updrs
KOL Index score: 13608

BACKGROUND: Levodopa is the most effective therapy for Parkinson's disease, but chronic treatment is associated with the development of potentially disabling motor complications. Experimental studies suggest that motor complications are due to non-physiological, intermittent administration of the drug, and can be reduced with continuous delivery. We aimed to assess efficacy and safety of levodopa-carbidopa intestinal gel delivered continuously through an intrajejunal percutaneous ...

Also Ranks for: Intestinal Gel |  advanced parkinson |  levodopa carbidopa |  continuous delivery |  motor complications
KOL Index score: 13458

BACKGROUND: Many patients with Parkinson's disease have potentially disabling off episodes that are not predictably responsive to levodopa. In this study, we assessed the safety and efficacy of apomorphine sublingual film as an on-demand therapy for off episodes in patients with Parkinson's disease.

METHODS: This randomised, double-blind, placebo-controlled study was done by movement disorder specialists at 32 sites in the USA and one in Canada. Patients with Parkinson's disease who had ...

Also Ranks for: Apomorphine Sublingual Film |  parkinsons disease |  episodes patients |  aged parkinson |  openlabel titration phase
KOL Index score: 13185

Rotigotine is a novel, non-ergoline dopamine D(3)/D(2)/D(1)-receptor agonist for the treatment of Parkinson's disease that can be continuously delivered by the transdermal route to provide stable plasma levels. Continuous drug delivery should reduce the risk of dyskinesia induction in comparison to pulsatile dopaminergic treatment. Thus the aim of the study was to compare the reversal of motor disability and induction of dyskinesia produced by continuous compared to pulsatile rotigotine ...

Also Ranks for: Dyskinesia Induction |  rotigotine administration |  continuous delivery |  motor disability |  common marmosets
KOL Index score: 12367

BACKGROUND: Trials are under way to determine whether fetal nigral grafts can improve motor function in patients with Parkinson's disease. Some studies use fluorodopa uptake on positron-emission tomography (PET) as a marker of graft viability, but fluorodopa uptake does not distinguish between host and grafted neurons. There has been no direct evidence that grafts of fetal tissue can survive and innervate the striatum.

METHODS: We studied a 59-year-old man with advanced Parkinson's ...

Also Ranks for: Graft Survival |  fetal mesencephalic tissue |  striatal reinnervation |  fluorodopa uptake |  patient parkinsons disease
KOL Index score: 11919

The objective of this study is to conduct a dose-finding study of sarizotan in Parkinson's disease (PD) patients with dyskinesia to identify a safe dose and to identify a sensitive dyskinesia rating measure. Sarizotan is a novel compound with full 5-HT(1A) agonist properties and additional high affinity for D(3) and D(4) receptors. An open label study documented improvements in PD patients with levodopa-induced dyskinesia. There is no precedent for study designs or outcome measures in ...

Also Ranks for: Patients Dyskinesia |  updrs items |  d4 receptors |  parkinsons disease |  additional affinity
KOL Index score: 11850

The Stalevo Reduction in Dyskinesia Evaluation in Parkinson's Disease (STRIDE-PD) study compared the initiation of levodopa (l-dopa) therapy with l-dopa/carbidopa (LC) versus l-dopa/carbidopa/entacapone (LCE) in patients with Parkinson's disease. In the current study, the STRIDE-PD study population was investigated to determine the effect of l-dopa dose and other risk factors on the development of dyskinesia and wearing-off. Patients were randomized to receive LCE (n=373) or LC (n=372). ...

Also Ranks for: Factors Predictive |  levodopa‐induced dyskinesia |  motor complication |  dose dopa |  patients parkinsons disease
KOL Index score: 11831

Nonmotor symptoms (NMS) of Parkinson's disease (PD) are not well recognized in clinical practice, either in primary or in secondary care, and are frequently missed during routine consultations. There is no single instrument (questionnaire or scale) that enables a comprehensive assessment of the range of NMS in PD both for the identification of problems and for the measurement of outcome. Against this background, a multidisciplinary group of experts, including patient group ...

Also Ranks for: Nonmotor Symptoms |  nmsquest study |  nms parkinsons disease |  comprehensive assessment |  screening tool
KOL Index score: 11372

A patient with Parkinson's disease received bilateral fetal human nigral implants from six donors aged 6.5 to 9 weeks post-conception. Eighteen months following a post-operative clinical course characterized by marked improvement in clinical function, this patient died from events unrelated to the grafting procedure. Post-mortem histological analyses revealed the presence of viable grafts in all 12 implant sites, each containing a heterogeneous population of neurons and glia. ...

Also Ranks for: Fetal Nigral |  grafted neurons |  host striatum |  patient parkinsons disease |  transport proteins
KOL Index score: 11252

BACKGROUND AND PURPOSE: Experimental studies suggest that deep brain stimulation (DBS) of the subthalamic nucleus (STN) induces impulsivity in patients with Parkinson's disease (PD). The purpose of this study was to assess various measures of impulse control in PD patients with STN DBS in comparison to patients receiving medical therapy.

METHODS: In a cross-sectional evaluation, 53 consecutively eligible patients were assessed for impulsivity with the Barratt Impulsiveness Scale, for ...

Also Ranks for: Impulse Control |  patients dbs |  deep brain |  impulsivity stn |  parkinson disease

Key People For Parkinson Disease

Top KOLs in the world
Andrew **** ******
parkinsons disease progressive supranuclear motor fluctuations
Anthony ****** ****
parkinson disease movement disorders subthalamic nucleus
Werner * *****
parkinson disease multiple atrophy restless legs syndrome
Christopher * *****
parkinson disease movement disorders rating scales
Charles * ******
parkinson disease oxidative stress motor complications
Joseph * ********
movement disorders parkinson disease essential tremor

Charles W Olanow:Expert Impact

Concepts for whichCharles W Olanowhas direct influence:Parkinson disease,  Parkinsons disease,  Oxidative stress,  Motor complications,  Movement disorders,  Myasthenia gravis,  Substantia nigra,  Cell death.

Charles W Olanow:KOL impact

Concepts related to the work of other authors for whichfor which Charles W Olanow has influence:Parkinson disease,  Oxidative stress,  Dopaminergic neurons,  Deep brain stimulation,  Substantia nigra,  Motor symptoms,  Subthalamic nucleus.



Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

Clintrex Research Corp, Sarasota, FL, USA | Mount Sinai School of Medicine, New York, NY, USA; Clintrex, Research Corporation, Sarasota, FL, USA. Electronic address: | Clintrex Research Corporation, Sarasota, Florida, USA